Trading of APIs.
Production of various APIs.
Venture into the manufacture of DC Paracetemol (PFI)
Targeting of OTC market in the US for Paracetemol PFI.
Expansion of PFI capacity.
Obtaining US FDA approval for PFI and other APIs.
Development of new PFIs such as Guaifenesin, Metformin and Ibuprofen etc.
Filing of new DMFs of the above PFIs and moving up of value chain in OTC products.
Setting up of the world's single largest PFI facility with a capacity of 7,200 TPA.
The only company in the world to manufacture combination PFIs on a commercial scale using different basic APIs with other excipients.
Addition of a Tableting facility with a capacity of one billion pieces per annum
Started construction of the Tableting facility with a capacity of 12 billion tablets.
Major expansion of Paracetamol facility, from a capacity of 3600 MT to 12000MT per annum.
